MAYNF (Mayne Pharma Group) Long-Term Debt: $1.4 Mil (As of Dec. 2025)


MAYNF Mayne Pharma Group Ltd MAYNF
52 GF Score
Price $1.65
GF Value $3.11
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Mayne Pharma Group Long-Term Debt?

Mayne Pharma Group MAYNF 52 Long-Term Debt is $1.4 Mil as of Dec. 2025. GuruFocus rates MAYNF with a GF Score™ of 52/100 and a GF Value™ of $3.11 (Possible Value Trap). The stock has 3 warning signs investors should review.

Mayne Pharma Group's Long-Term Debt for the quarter that ended in Dec. 2025 was $1.4 Mil.

Mayne Pharma Group's quarterly Long-Term Debt declined from Dec. 2024 ($1.8 Mil) to Jun. 2025 ($0.0 Mil) but then increased from Jun. 2025 ($0.0 Mil) to Dec. 2025 ($1.4 Mil).

Mayne Pharma Group's annual Long-Term Debt increased from Jun. 2023 ($19.1 Mil) to Jun. 2024 ($21.0 Mil) but then declined from Jun. 2024 ($21.0 Mil) to Jun. 2025 ($0.0 Mil).

Mayne Pharma Group  (OTCPK:MAYNF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Mayne Pharma Group Long-Term Debt Related Terms

Mayne Pharma Group Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Mayne Pharma Group's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mayne Pharma Group Long-Term Debt Chart

Mayne Pharma Group Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 218.50 0.00 19.11 21.01 0.00

Mayne Pharma Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.16 21.01 1.78 0.00 1.43
MAYNF
52GF Score
Mayne Pharma Group Ltd MAYNF
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $1.4 Mil mean?
Mayne Pharma Group (MAYNF) has a Long-Term Debt of $1.4 Mil as of Dec. 2025.
Is Mayne Pharma Group's Long-Term Debt too high?
Mayne Pharma Group's current Long-Term Debt is $1.4 Mil. Overall, Mayne Pharma Group has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's Long-Term Debt compare to MCK and CAH?
Mayne Pharma Group's Long-Term Debt of $1.4 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Distribution company?
A good Long-Term Debt depends on the Medical Distribution industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Mayne Pharma Group's current Long-Term Debt is $1.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (MAYNF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.11, compared to a current price of $1.65 — trading 46.9% below its estimated fair value. The current Long-Term Debt is $1.4 Mil. Mayne Pharma Group's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Mayne Pharma Group (MAYNF), the current Long-Term Debt is $1.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mayne Pharma Group (MAYNF) Overvalued in 2026?

Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued. The current stock price of $1.65 is trading 46.9% below its estimated GF Value™ of $3.11. GuruFocus considers Mayne Pharma Group to be Possible Value Trap.

Key valuation signals for MAYNF:

  • Long-Term Debt: $1.4 Mil
  • GF Value™: $3.11 vs. price of $1.65 (46.9% below fair value)
  • GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the MAYNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mayne Pharma Group Business Description

Other Exchanges MYX:Australia
Address 1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
52GF Score

Get the complete analysis for MAYNF

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.65
Price
$3.11
GF Value